Abstract
The SARS-CoV-2 pandemic and subsequent interruption of influenza circulation has lowered population immunity to influenza, especially among children with few pre-pandemic exposures. We compared the incidence and severity of influenza A/H3N2 and influenza B/Victoria between 2022 and two pre-pandemic seasons and found an increased frequency of severe influenza in 2022.
Competing Interest Statement
A.G. serves on a scientific advisory board for Janssen Pharmaceuticals. G.H., H.M., G.K., N.S., R.L., A.M., M.P., S.O., and A.B. report no conflicts of interest.
Funding Statement
This work was supported by the National Institute for Allergy and Infectious Disease [U01 AI088654 and U01 AI144616; and contract numbers HHSN272201400006C and 75N93021C00016 to A.G.]. Aubree Gordon is supported by the Biosciences Initiative at the University of Michigan through a Mid-career Biosciences Faculty Achievement Award (MBioFAR). The funding agencies had no role in the design and conduct of the study, collection, management, analysis or interpretation of the data; preparation, review, or approval of the manuscript; or decision to submit the manuscript for publication.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The IRBs of the Nicaraguan Ministry of Health and the University of Michigan gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Alternative contact: Gregory Hoy, 1415 Washington Heights, Ann Arbor, MI, USA 48109-2029, e: ghoy{at}umich.edu, t: (254) 537-2120
Data Availability
All data produced in the present study are available upon reasonable request to the authors.
